Native‐like Env trimers as a platform for HIV‐1 vaccine design
RW Sanders, JP Moore - Immunological reviews, 2017 - Wiley Online Library
We describe the development and potential use of various designs of recombinant HIV‐1
envelope glycoprotein trimers that mimic the structure of the virion‐associated spike, which …
envelope glycoprotein trimers that mimic the structure of the virion‐associated spike, which …
Identification and specificity of broadly neutralizing antibodies against HIV
LE McCoy, DR Burton - Immunological reviews, 2017 - Wiley Online Library
Beginning in 2009, studies of the humoral responses of HIV‐positive individuals have led to
the identification of scores, if not hundreds, of antibodies that are both broadly reactive and …
the identification of scores, if not hundreds, of antibodies that are both broadly reactive and …
Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies
LE McCoy, MJ van Gils, G Ozorowski, T Messmer… - Cell reports, 2016 - cell.com
A major advance in the search for an HIV vaccine has been the development of a near-
native Envelope trimer (BG505 SOSIP. 664) that can induce robust autologous Tier 2 …
native Envelope trimer (BG505 SOSIP. 664) that can induce robust autologous Tier 2 …
Major scientific hurdles in HIV vaccine development: historical perspective and future directions
T Ng'uni, C Chasara, ZM Ndhlovu - Frontiers in immunology, 2020 - frontiersin.org
Following the discovery of HIV as a causative agent of AIDS, the expectation was to rapidly
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …
Quantification of the impact of the HIV-1-glycan shield on antibody elicitation
While the HIV-1-glycan shield is known to shelter Env from the humoral immune response,
its quantitative impact on antibody elicitation has been unclear. Here, we use targeted …
its quantitative impact on antibody elicitation has been unclear. Here, we use targeted …
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice
The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-
19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope …
19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope …
Completeness of HIV-1 envelope glycan shield at transmission determines neutralization breadth
Densely arranged N-linked glycans shield the HIV-1 envelope (Env) trimer from antibody
recognition. Strain-specific breaches in this shield (glycan holes) can be targets of vaccine …
recognition. Strain-specific breaches in this shield (glycan holes) can be targets of vaccine …
Vaccine induction of heterologous tier 2 HIV-1 neutralizing antibodies in animal models
KO Saunders, LK Verkoczy, C Jiang, J Zhang, R Parks… - Cell reports, 2017 - cell.com
The events required for the induction of broad neutralizing antibodies (bnAbs) following HIV-
1 envelope (Env) vaccination are unknown, and their induction in animal models as proof of …
1 envelope (Env) vaccination are unknown, and their induction in animal models as proof of …
RAB11FIP5 expression and altered natural killer cell function are associated with induction of HIV broadly neutralizing antibody responses
HIV-1 broadly neutralizing antibodies (bnAbs) are difficult to induce with vaccines but are
generated in∼ 50% of HIV-1-infected individuals. Understanding the molecular …
generated in∼ 50% of HIV-1-infected individuals. Understanding the molecular …